Why Telik (TELK) Stock Is Soaring Today
at The Street - Tue May 13, 11:06AM CDT
Telik (TELK) soared Tuesday after Monday's announcement that the oncology drug development company had entered into a definitive merger agreement with privately held MabVax Therapeutics.
Telik, Biotech Pariah, Finally Died
at The Street - Mon May 12, 5:24PM CDT
Telik never recovered from hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta in 2007
MabVax Therapeutics And Telik Sign Definitive Merger Agreement
PR Newswire - Mon May 12, 3:30PM CDT
MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug development company have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction. The boards of directors of both companies have approved the merger and the stockholders of MabVax have also approved the merger. The merger is subject to the approval of the Telik stockholders as well as other customary conditions. Upon the closing of the transaction, Telik will be re-named MabVax Therapeutics Holdings, Inc. and will operate under the leadership of the MabVax management team with J. David Hansen, president and CEO of MabVax, serving as the President, CEO, and Chairman of the Board. Michael M. Wick, M.D., Ph.D., who currently serves as President and CEO of Telik, will remain on the board.
Telik and MabVax Therapeutics Announce Definitive Merger Agreement
PR Newswire - Mon May 12, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK), a clinical stage oncology drug development company, and MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction. The boards of directors of both companies have approved the merger and the stockholders of MabVax have also approved the merger. The merger is subject to the approval of the Telik stockholders as well as other customary conditions. Upon the closing of the transaction, Telik will be re-named MabVax Therapeutics Holdings, Inc. and will operate under the leadership of the MabVax management team with J. David Hansen, President and CEO of MabVax, serving as the President, CEO, and Chairman of the Board. Michael M. Wick, M.D., Ph.D., who currently serves as President and CEO of Telik, will remain on the board.
Neutropenia Therapeutic Pipeline Review 2014 - Analysis of 16 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl9vgd/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Hospira, Inc. - Gamida Cell Ltd. - Ligand Pharmaceuticals, Inc. - Cleveland BioLabs, Inc. - Telik, Inc. - ProMetic Life Sciences Inc. - Green Cross Corporation - Cellerant Therapeutics, Inc. - Genexine, Inc. - Bolder Biotechnology, Inc. - USV Limited - Pfenex Inc. - Mycenax Biotech Inc. - NAL Pharmaceuticals Ltd. - Inbiopro Solutions Pvt. Ltd. - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - GCPGC - filgrastim biosimilar - MG-1107 - ezatiostat hydrochloride - HM-10460A - GC-003 - romyelocel L - Human Serum Albumin Fusion Protein Drug - GX-G3 - filgrastim - pegfilgrastim biosimilar - filgrastim biosimilar - CBLB-612 - PBI-4050 - BBT-015 - BBT-018 - BBT-007 - pegfilgrastim biosimilar - IBPB-004-IG - LG-7455 - ACN-8337 - pegfilgrastim biosimilar - Pegylated Granulocyte Colony Stimulating Factor Biosimilar - granulocyte colony-stimulating factor biobetter - Hemokine For more information visit http://www.researchandmarkets.com/research/sl...eutropenia
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Telik Announces Fourth Quarter And 2013 Year End Financial Results
PR Newswire - Mon Mar 10, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.8 million, or $0.17 per share, for the three months ended December 31, 2013, compared with a net loss of $1.8 million, or $0.66 per share, for the comparable period in 2012. For the year ended December 31, 2013, net loss was $5.2 million, or $1.17 per share, compared with a net loss of $8.0 million, or $3.64 per share, for the year ended December 31, 2012.
Sears Holdings Announces Date For 2014 Annual Meeting Of Stockholders
PR Newswire - Wed Jan 22, 3:47PM CST
Sears Holdings Corporation (NASDAQ: SHLD) announced today that the 2014 annual meeting of stockholders will be held at the Company's headquarters in Hoffman Estates, Ill., on Tuesday, May 6, 2014.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola
GlobeNewswire - Tue Jan 14, 12:52PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has dosed the first subject in a Phase I human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense.
Tesla Provides Customers With Upgraded Charging Software and Adapter
Marketwire - Fri Jan 10, 3:51PM CST
A variety of factors such as corrosion, physical damage to receptacles, or inappropriate wiring or installation of electrical outlets can cause higher than normal electrical resistance when using the Universal Mobile Connector ("UMC"
Telik Announces Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 3:20PM CST
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.1 million, or $0.25 per share, for the third quarter ended September 30, 2013, compared with a net loss of $1.9 million, or $0.78 per share for the comparable period in 2012.
OTC Signal Daily Stock Watch - Telik, Inc., (NASDAQ: TELK)
WorldStockWire - Wed Sep 04, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Telik Announces Second Quarter 2013 Financial Results
PR Newswire - Fri Aug 09, 3:15PM CDT
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.4 million, or $0.30 per share, for the second quarter ended June 30, 2013, compared with a net loss of $2.1 million, or $1.11 per share for the comparable period in 2012.
Acute Promyelocytic Leukemia - Pipeline Review, H1 2013
M2 - Tue Jul 16, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hn2mbb/acute) has announced the addition of the "Acute Promyelocytic Leukemia - Pipeline Review, H1 2013" report to their offering. 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. Scope - A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia. - A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature
Market Maker Surveillance Report. TELK, FSLR, IEP, KNDI, ECTE, AOSL, Losing Stocks With Lowest Price Friction For Wednesday, June 12th 2013
M2 - Thu Jun 13, 2:20AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3761 companies with "abnormal" market making, 1577 companies with positive Friction Factors and 3797 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Telik Inc (NASDAQ:TELK), First Solar Inc (NASDAQ:FSLR), Icahn Enterprises LP (NASDAQ:IEP), Kandi Technologies Corp (NASDAQ:KNDI), Echo Therapeutics Inc (NASDAQ:ECTE), Alpha and Omega Semiconductor Ltd (NASDAQ:AOSL). To access Friction Factor, Naked Short Data a
Telik Announces First Quarter 2013 Financial Results
PR Newswire - Fri May 10, 3:30PM CDT
Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2013. The net loss for the quarter ended March 31, 2013 was $1.9 million, or $0.46 per share, compared with a net loss of $2.3 million, or $1.25 per share, for the same period in 2012.
Mantle Cell Lymphoma - Pipeline Review, H1 2013 Featuring 22 Major Companies
M2 - Thu Apr 18, 6:22AM CDT
Research and Markets has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. 'Mantle Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mantle Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication t
Brain Tumor - Pipeline Review, H1 2013
M2 - Thu Mar 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zmbpg/brain_tumor) has announced the addition of the "Brain Tumor - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Brain Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Tumor. Scope - A snapshot of the global therapeutic scenario for Brain Tumor. - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therap